By Josh Beckerman

LAVA Therapeutics NV shares were up 7% to $7.70 Wednesday after a potential treatment of chronic lymphocytic leukemia received an orphan drug designation from the U.S. Food and Drug Administration.

The FDA lists the generic name of the potential treatment as immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

10-13-21 1436ET